Cytokinetics Reports Second Quarter 2024 Financial Results

Cytokinetics Reports Second Quarter 2024 Financial Results · $1.4 billion in cash, cash equivalents and investments compared to · $634.3 million ...

Cytokinetics Reports Second Quarter 2024 Financial Results. August 8, 2024 8:00 PM EDT. Type B Meeting Held with FDA Related to Potential Risk Mitigation ...

Cytokinetics Reports Second Quarter 2024 Financial Results

Net loss for the second quarter of 2024 was $143.3 million, or $(1.31) per share, basic and diluted, compared to a net loss of $128.6 million, ...

Cytokinetics Reports Second Quarter 2024 Financial Results

Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten;Company Has Initiated Rolling NDA Submission FDA ...

Cytokinetics to Announce Second Quarter Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif. , July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled ...

Cytokinetics Reports Second Quarter 2024 Financial Results

Cytokinetics Reports Second Quarter 2024 Financial Results · Net loss increased to $143.3 million in Q2 2024 compared to $128.6 million in Q2 ...

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and ...

Cytokinetics to Announce Second Quarter Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is ...

Press Releases | Cytokinetics, Inc.

... 2024. Aug. 29. 2024. Cytokinetics to Participate in September Investor Conferences. Aug. 08. 2024. Cytokinetics Reports Second Quarter 2024 Financial Results.

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Cytokinetics (CYTK) will report its second quarter 2024 financial results on August 8, 2024, at 4:00 PM Eastern Time. How can investors access ...

Cytek Biosciences Reports Second Quarter 2024 Financial Results

Total revenue for the second quarter of 2024 was $46.6 million, a 6% decrease compared to the second quarter of 2023. The decline in revenue was related to ...

Cytokinetics Reports Second Quarter 2024 Financial Results

Total revenues for the second quarter of 2024 were $0.2 million compared to $0.9 million for the same period in 2023. Research and Development ( ...

Cytokinetics Reports Third Quarter 2024 Financial Results

Cytokinetics Reports Third Quarter 2024 Financial Results ; Cash, Cash Equivalents and Investments. As of September 30, 2024 , the company had ...

Cytokinetics Reports Third Quarter 2024 Financial Results - Nasdaq

G&A expenses for the third quarter of 2024 were $56.7 million which included $13.9 million of non-cash stock-based compensation expense, ...

Cytokinetics, Inc.: Investor Overview

Q3 2024 Cytokinetics, Inc. Earnings Conference Call. Nov. 06. 2024. 4:30 PM ... 2023 Annual Report. 2023 Annual Report. Download 7.9 MB. Read more. Corporate ...

Cytokinetics 8K Reports Second Quarter 2024 Financial Results ...

Cytokinetics (CYTK) 8-KCytokinetics Reports Second Quarter 2024 Financial Results ; 350 Oyster Point Boulevard ; South San Francisco, California ; (Address of ...

Cytokinetics Q2 2024 Financial Results Released - Patsnap Synapse

Revenue for Q2 2024 was $0.2 million, down from $0.9 million in Q2 2023. R&D expenses decreased to $79.6 million, while G&A expenses rose to ...

Royalty Pharma Reports Second Quarter 2024 Results

2024 Portfolio Receipts guidance includes expected year/year growth in Royalty Receipts of 9% to 12% (previous guidance of 5% to 9% year/year ...

Cytokinetics on X: "$CYTK Investors: We reported our second ...

CYTK Investors: We reported our second quarter 2024 financial results today. Our senior management team will provide more details in a ...

Cytokinetics Reports Second Quarter 2022 Financial Results

Net loss for the second quarter was $19.8 million , or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million , ...